* 출처 : 서울아산병원

제13회 GIST환우 모임

2016년 5월 28일 / 서울아산병원 대강당

서울아산병원 종양내과 

강윤구 교수

진료과: 종양내과,암병원,간센터,간암센터,위암센터

전문진료분야: 위암,간암,GIST,소화기육종

학력 사항

서울대학교 의학 학사

서울대학교 의학 석사

서울대학교 의학 학사

교육 및 연구 경력

현)울산대학교 의과대학 서울아산병원 종양내과 교수

현)대한항암요법연구회 회장

주요 업적 

<논문>

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas.

Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients.

Clinical and histopathological analysis of 46 cases of cutaneous adverse reactions to imatinib

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.

Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer.

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.

Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.